| Abstract: | Being able to carry zidovudine (AZT) at known concentrations into CD4+/CD38+ and CD14+ cells permits:| – |
- to reduce the drug dosage and to increase the interval for administration (until 1 dose I.V. every week);
| | – |
- to modulate the drug concentration into the CD4+/CD38 an CD14+ cells in relation to the  in vitro determined HIV sensitiveness;
| | – |
- to eliminate haematological, medullary and general toxicity;
| | – |
- to be able to treat severely hill patients.
|
Further studies are necessary in order to:| – |
- To find out the better phase to start the therapy;
| | – |
- To use several drugs with different mechanisms of action in order to slow down as much as possible the presence of resistant viral strains.
| | – |
- As for other drugs which are beginning to be used with artificial vehicles, futher studies are required to improve the selectivity and safety of LIPOAZT for the target cells including macrophages.
|
|
